Laverock Therapeutics, a Stevenage, UK-based provider of a gene silencing platform, raised £13.5M in Seed funding.
The round was led by Calculus Capital with participation from Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures.
Established in 2021 and led by CEO David Venables, Laverock Therapeutics is developing a gene silencing platform for the creation of programmable advanced human therapeutic applications. GEiGS uses universal gene editing tools to minimally edit non-coding genes and redirect their silencing activity (RNAi) towards a new target gene. It is differentiated from other gene silencing approaches through its core stable, tunable and programmable attributes, ensuring cell type- or condition-specific activity.
The company intends to use the funds to further development of its GEiGS technology and progression of its programs in regenerative medicine and immuno-oncology, with a focus on Type I Diabetes and solid tumour responsive T-cell and macrophage based immune therapies, through to in vitro and in vivo validation. A key part of this next phase will be bringing on new members of the team and expanding lab facilities.
FinSMEs
28/09/2023